LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Cleavage fragments of the C-terminal tail of polycystin-1 are regulated by oxidative stress and induce mitochondrial dysfunction.

    Pellegrini, Hannah / Sharpe, Elizabeth H / Liu, Guangyi / Nishiuchi, Eiko / Doerr, Nicholas / Kipp, Kevin R / Chin, Tiffany / Schimmel, Margaret F / Weimbs, Thomas

    The Journal of biological chemistry

    2023  Volume 299, Issue 9, Page(s) 105158

    Abstract: Mutations in the gene encoding polycystin-1 (PC1) are the most common cause of autosomal dominant polycystic kidney disease (ADPKD). Cysts in ADPKD exhibit a Warburg-like metabolism characterized by dysfunctional mitochondria and aerobic glycolysis. PC1 ... ...

    Abstract Mutations in the gene encoding polycystin-1 (PC1) are the most common cause of autosomal dominant polycystic kidney disease (ADPKD). Cysts in ADPKD exhibit a Warburg-like metabolism characterized by dysfunctional mitochondria and aerobic glycolysis. PC1 is an integral membrane protein with a large extracellular domain, a short C-terminal cytoplasmic tail and shares structural and functional similarities with G protein-coupled receptors. Its exact function remains unclear. The C-terminal cytoplasmic tail of PC1 undergoes proteolytic cleavage, generating soluble fragments that are overexpressed in ADPKD kidneys. The regulation, localization, and function of these fragments is poorly understood. Here, we show that a ∼30 kDa cleavage fragment (PC1-p30), comprising the entire C-terminal tail, undergoes rapid proteasomal degradation by a mechanism involving the von Hippel-Lindau tumor suppressor protein. PC1-p30 is stabilized by reactive oxygen species, and the subcellular localization is regulated by reactive oxygen species in a dose-dependent manner. We found that a second, ∼15 kDa fragment (PC1-p15), is generated by caspase cleavage at a conserved site (Asp-4195) on the PC1 C-terminal tail. PC1-p15 is not subject to degradation and constitutively localizes to the mitochondrial matrix. Both cleavage fragments induce mitochondrial fragmentation, and PC1-p15 expression causes impaired fatty acid oxidation and increased lactate production, indicative of a Warburg-like phenotype. Endogenous PC1 tail fragments accumulate in renal cyst-lining cells in a mouse model of PKD. Collectively, these results identify novel mechanisms regarding the regulation and function of PC1 and suggest that C-terminal PC1 fragments may be involved in the mitochondrial and metabolic abnormalities observed in ADPKD.
    MeSH term(s) Animals ; Mice ; Mitochondrial Diseases ; Oxidative Stress ; Polycystic Kidney, Autosomal Dominant/metabolism ; Reactive Oxygen Species/metabolism ; TRPP Cation Channels/genetics ; TRPP Cation Channels/metabolism
    Chemical Substances Reactive Oxygen Species ; TRPP Cation Channels ; polycystic kidney disease 1 protein
    Language English
    Publishing date 2023-08-12
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2997-x
    ISSN 1083-351X ; 0021-9258
    ISSN (online) 1083-351X
    ISSN 0021-9258
    DOI 10.1016/j.jbc.2023.105158
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Restoration of atypical protein kinase C ζ function in autosomal dominant polycystic kidney disease ameliorates disease progression.

    Akbari, Masaw / West, Jonathan D / Doerr, Nicholas / Kipp, Kevin R / Marhamati, Neda / Vuong, Sabrina / Wang, Yidi / Rinschen, Markus M / Talbot, Jeffrey J / Wessely, Oliver / Weimbs, Thomas

    Proceedings of the National Academy of Sciences of the United States of America

    2022  Volume 119, Issue 30, Page(s) e2121267119

    Abstract: Autosomal dominant polycystic kidney disease (ADPKD) affects more than 500,000 individuals in the United States alone. In most cases, ADPKD is caused by a loss-of-function mutation in ... ...

    Abstract Autosomal dominant polycystic kidney disease (ADPKD) affects more than 500,000 individuals in the United States alone. In most cases, ADPKD is caused by a loss-of-function mutation in the
    MeSH term(s) Animals ; Disease Models, Animal ; Disease Progression ; Enzyme Activation ; Fingolimod Hydrochloride/pharmacology ; Fingolimod Hydrochloride/therapeutic use ; Humans ; Mice ; Polycystic Kidney, Autosomal Dominant/drug therapy ; Polycystic Kidney, Autosomal Dominant/enzymology ; Protein Kinase C/metabolism ; TRPP Cation Channels/genetics ; TRPP Cation Channels/metabolism
    Chemical Substances TRPP Cation Channels ; protein kinase C zeta (EC 2.7.11.1) ; Protein Kinase C (EC 2.7.11.13) ; Fingolimod Hydrochloride (G926EC510T)
    Language English
    Publishing date 2022-07-22
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, N.I.H., Extramural
    ZDB-ID 209104-5
    ISSN 1091-6490 ; 0027-8424
    ISSN (online) 1091-6490
    ISSN 0027-8424
    DOI 10.1073/pnas.2121267119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with

    Nelson, Luke J / Castro, Kyleen E / Xu, Binzhi / Li, Junyi / Dinh, Nguyen B / Thompson, Jordan M / Woytash, Jordan / Kipp, Kevin R / Razorenova, Olga V

    Cell cycle (Georgetown, Tex.)

    2022  Volume 21, Issue 10, Page(s) 1103–1119

    Abstract: Clear cell renal cell carcinoma (CC-RCC) remains one of the most deadly forms of kidney cancer despite recent advancements in targeted therapeutics, including tyrosine kinase and immune checkpoint inhibitors. Unfortunately, these therapies have not been ... ...

    Abstract Clear cell renal cell carcinoma (CC-RCC) remains one of the most deadly forms of kidney cancer despite recent advancements in targeted therapeutics, including tyrosine kinase and immune checkpoint inhibitors. Unfortunately, these therapies have not been able to show better than a 16% complete response rate. In this study we evaluated a cyclin-dependent kinase inhibitor, Dinaciclib, as a potential new targeted therapeutic for CC-RCC.
    MeSH term(s) Animals ; Carcinoma, Renal Cell/genetics ; Cell Line, Tumor ; Cyclic N-Oxides ; Cyclin-Dependent Kinase Inhibitor Proteins/genetics ; Cyclin-Dependent Kinases/genetics ; Female ; Humans ; Indolizines ; Kidney Neoplasms/pathology ; Male ; Mice ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyridinium Compounds ; Synthetic Lethal Mutations ; Von Hippel-Lindau Tumor Suppressor Protein/genetics ; Von Hippel-Lindau Tumor Suppressor Protein/metabolism
    Chemical Substances Cyclic N-Oxides ; Cyclin-Dependent Kinase Inhibitor Proteins ; Indolizines ; Protein Kinase Inhibitors ; Pyridinium Compounds ; dinaciclib (4V8ECV0NBQ) ; Von Hippel-Lindau Tumor Suppressor Protein (EC 2.3.2.27) ; Cyclin-Dependent Kinases (EC 2.7.11.22) ; VHL protein, human (EC 6.3.2.-)
    Language English
    Publishing date 2022-03-04
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2146183-1
    ISSN 1551-4005 ; 1538-4101 ; 1554-8627
    ISSN (online) 1551-4005
    ISSN 1538-4101 ; 1554-8627
    DOI 10.1080/15384101.2022.2041783
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease.

    Kipp, Kevin R / Rezaei, Mina / Lin, Louis / Dewey, Elyse C / Weimbs, Thomas

    American journal of physiology. Renal physiology

    2016  Volume 310, Issue 8, Page(s) F726–F731

    Abstract: Autosomal-dominant polycystic kidney disease (ADPKD) is a common cause of end-stage renal disease, and no approved treatment is available in the United States to slow disease progression. The mammalian target of rapamycin (mTOR) signaling pathway is ... ...

    Abstract Autosomal-dominant polycystic kidney disease (ADPKD) is a common cause of end-stage renal disease, and no approved treatment is available in the United States to slow disease progression. The mammalian target of rapamycin (mTOR) signaling pathway is aberrantly activated in renal cysts, and while mTOR inhibitors are highly effective in rodent models, clinical trials in ADPKD have been disappointing due to dose-limiting extrarenal side effects. Since mTOR is known to be regulated by nutrients and cellular energy status, we hypothesized that dietary restriction may affect renal cyst growth. Here, we show that reduced food intake (RFI) by 23% profoundly affects polycystic kidneys in an orthologous mouse model of ADPKD with a mosaic conditional knockout of PKD1. This mild level of RFI does not affect normal body weight gain, cause malnutrition, or have any other apparent side effects. RFI substantially slows disease progression: relative kidney weight increase was 41 vs. 151% in controls, and proliferation of cyst-lining cells was 7.7 vs. 15.9% in controls. Mice on an RFI diet maintained kidney function and did not progress to end-stage renal disease. The two major branches of mTORC1 signaling, S6 and 4EBP1, are both suppressed in cyst-lining cells by RFI, suggesting that this dietary regimen may be more broadly effective than pharmacological mTOR inhibition with rapalogs, which primarily affects the S6 branch. These results indicate that polycystic kidneys are exquisitely sensitive to minor reductions in nutrient supply or energy status. This study suggests that a mild decrease in food intake represents a potential therapeutic intervention to slow disease progression in ADPKD patients.
    MeSH term(s) Animals ; Caloric Restriction ; Disease Models, Animal ; Disease Progression ; Eating/physiology ; Kidney/metabolism ; Mice ; Polycystic Kidney Diseases/diet therapy ; Polycystic Kidney Diseases/metabolism ; Signal Transduction/physiology ; TOR Serine-Threonine Kinases/metabolism ; TRPP Cation Channels/genetics ; TRPP Cation Channels/metabolism
    Chemical Substances TRPP Cation Channels ; polycystic kidney disease 1 protein ; MTOR protein, human (EC 2.7.1.1) ; TOR Serine-Threonine Kinases (EC 2.7.1.1)
    Language English
    Publishing date 2016-04-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603837-2
    ISSN 1522-1466 ; 0363-6127
    ISSN (online) 1522-1466
    ISSN 0363-6127
    DOI 10.1152/ajprenal.00551.2015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.

    Kipp, Kevin R / Kruger, Samantha L / Schimmel, Margaret F / Parker, Nikki / Shillingford, Jonathan M / Leamon, Christopher P / Weimbs, Thomas

    American journal of physiology. Renal physiology

    2018  Volume 315, Issue 2, Page(s) F395–F405

    Abstract: Autosomal-dominant polycystic kidney disease (ADPKD) is a very common genetic disease leading to renal failure. Numerous aberrantly regulated signaling pathways have been identified as promising molecular drug targets for ADPKD therapy. In rodent models, ...

    Abstract Autosomal-dominant polycystic kidney disease (ADPKD) is a very common genetic disease leading to renal failure. Numerous aberrantly regulated signaling pathways have been identified as promising molecular drug targets for ADPKD therapy. In rodent models, many small-molecule drugs against such targets have proven effective in reducing renal cyst growth. For example, mammalian target of rapamycin (mTOR) inhibition with rapamycin greatly ameliorates renal cystic disease in several rodent models. However, clinical trials with mTOR inhibitors were disappointing largely due to the intolerable extrarenal side effects during long-term treatment with these drugs. Most other potential drug targets in ADPKD are also widely expressed in extrarenal tissues, which makes it likely that untargeted therapies with small-molecule inhibitors against such targets will lead to systemic adverse effects during the necessary long-term treatment of years and decades in ADPKD patients. To overcome this problem, we previously demonstrated that folate-conjugated rapamycin (FC-rapa) targets polycystic kidneys due to the high expression of the folate receptor (FRα) and that treatment of a nonortholgous PKD mouse model leads to inhibition of renal cyst growth. Here we show, in a head-to-head comparison with unconjugated rapamycin, that FCrapa inhibits renal cyst growth, mTOR activation, cell cycling, and fibrosis in an orthologous Pkd1 mouse model. Both unconjugated rapamycin and FC-rapa are similarly effective on polycystic kidneys in this model. However, FC-rapa lacks the extrarenal effects of unconjugated rapamycin, in particular immunosuppressive effects. We conclude that folate-conjugation is a promising avenue for increasing the tissue specificity of small-molecule compounds to facilitate very long-term treatment in ADPKD.
    MeSH term(s) A549 Cells ; Animals ; Disease Models, Animal ; Drug Compounding ; Folate Receptor 1/metabolism ; Folic Acid/analogs & derivatives ; Folic Acid/metabolism ; Folic Acid/pharmacology ; Humans ; Integrases/genetics ; Kidney/drug effects ; Kidney/enzymology ; Mice, Knockout ; Polycystic Kidney, Autosomal Dominant/enzymology ; Polycystic Kidney, Autosomal Dominant/genetics ; Polycystic Kidney, Autosomal Dominant/prevention & control ; Protein Kinase Inhibitors/metabolism ; Protein Kinase Inhibitors/pharmacology ; Signal Transduction/drug effects ; Sirolimus/analogs & derivatives ; Sirolimus/metabolism ; Sirolimus/pharmacology ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; TOR Serine-Threonine Kinases/metabolism ; TRPP Cation Channels/deficiency ; TRPP Cation Channels/genetics ; Tissue Distribution
    Chemical Substances Folate Receptor 1 ; Folr1 protein, mouse ; Protein Kinase Inhibitors ; TRPP Cation Channels ; polycystic kidney disease 1 protein ; Folic Acid (935E97BOY8) ; TOR Serine-Threonine Kinases (EC 2.7.1.1) ; mTOR protein, mouse (EC 2.7.1.1) ; Cre recombinase (EC 2.7.7.-) ; Integrases (EC 2.7.7.-) ; Sirolimus (W36ZG6FT64)
    Language English
    Publishing date 2018-05-02
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 603837-2
    ISSN 1522-1466 ; 0363-6127
    ISSN (online) 1522-1466
    ISSN 0363-6127
    DOI 10.1152/ajprenal.00057.2018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Regulation of Polycystin-1 Function by Calmodulin Binding.

    Doerr, Nicholas / Wang, Yidi / Kipp, Kevin R / Liu, Guangyi / Benza, Jesse J / Pletnev, Vladimir / Pavlov, Tengis S / Staruschenko, Alexander / Mohieldin, Ashraf M / Takahashi, Maki / Nauli, Surya M / Weimbs, Thomas

    PloS one

    2016  Volume 11, Issue 8, Page(s) e0161525

    Abstract: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common genetic disease that leads to progressive renal cyst growth and loss of renal function, and is caused by mutations in the genes encoding polycystin-1 (PC1) and polycystin-2 (PC2), ... ...

    Abstract Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common genetic disease that leads to progressive renal cyst growth and loss of renal function, and is caused by mutations in the genes encoding polycystin-1 (PC1) and polycystin-2 (PC2), respectively. The PC1/PC2 complex localizes to primary cilia and can act as a flow-dependent calcium channel in addition to numerous other signaling functions. The exact functions of the polycystins, their regulation and the purpose of the PC1/PC2 channel are still poorly understood. PC1 is an integral membrane protein with a large extracytoplasmic N-terminal domain and a short, ~200 amino acid C-terminal cytoplasmic tail. Most proteins that interact with PC1 have been found to bind via the cytoplasmic tail. Here we report that the PC1 tail has homology to the regulatory domain of myosin heavy chain including a conserved calmodulin-binding motif. This motif binds to CaM in a calcium-dependent manner. Disruption of the CaM-binding motif in PC1 does not affect PC2 binding, cilia targeting, or signaling via heterotrimeric G-proteins or STAT3. However, disruption of CaM binding inhibits the PC1/PC2 calcium channel activity and the flow-dependent calcium response in kidney epithelial cells. Furthermore, expression of CaM-binding mutant PC1 disrupts cellular energy metabolism. These results suggest that critical functions of PC1 are regulated by its ability to sense cytosolic calcium levels via binding to CaM.
    MeSH term(s) Amino Acid Motifs ; Animals ; Binding Sites ; CHO Cells ; Calcium/metabolism ; Calmodulin/metabolism ; Cilia ; Cricetulus ; Cytoplasm/metabolism ; Cytosol/metabolism ; Dogs ; HEK293 Cells ; Humans ; Kidney/metabolism ; Madin Darby Canine Kidney Cells ; Mice ; Mutation ; Myosin Heavy Chains/chemistry ; Pectinidae ; Polycystic Kidney, Autosomal Dominant/metabolism ; Protein Domains ; STAT3 Transcription Factor/metabolism ; Signal Transduction ; TRPP Cation Channels/metabolism ; Transcription Factor AP-1/metabolism
    Chemical Substances Calmodulin ; STAT3 Transcription Factor ; TRPP Cation Channels ; Transcription Factor AP-1 ; polycystic kidney disease 1 protein ; Myosin Heavy Chains (EC 3.6.4.1) ; Calcium (SY7Q814VUP)
    Language English
    Publishing date 2016-08-25
    Publishing country United States
    Document type Journal Article
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0161525
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Signal transduction responses to lysophosphatidic acid and sphingosine 1-phosphate in human prostate cancer cells.

    Gibbs, Terra C / Rubio, Maria V / Zhang, Zhihong / Xie, Yuhuan / Kipp, Kevin R / Meier, Kathryn E

    The Prostate

    2009  Volume 69, Issue 14, Page(s) 1493–1506

    Abstract: Background: Lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are lipid mediators that bind to G-protein-coupled receptors. In this study, signaling responses to 18:1 LPA and S1P were examined in parallel in three human prostate cancer cell ... ...

    Abstract Background: Lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are lipid mediators that bind to G-protein-coupled receptors. In this study, signaling responses to 18:1 LPA and S1P were examined in parallel in three human prostate cancer cell lines: PC-3, Du145, and LNCaP.
    Methods: Receptor expression was assessed by RT-PCR, Northern blotting, and immunoblotting. Cellular responses to mediators were studied by proliferation assays, phosphoprotein immunoblotting, and phospholipid metabolism assays.
    Results: All cell lines express mRNA for both LPA and S1P receptors. PC-3 and Du145, but not LNCaP, proliferate in response to LPA and S1P. Epidermal growth factor (EGF), phorbol 12-myristate 13-acetate (PMA), LPA, and S1P induce activation of Erks in PC-3 and Du145; only EGF and PMA activate Erks in LNCaP. In Du145 and PC-3, Akt is activated by EGF, LPA, and S1P. Akt is constitutively active in LNCaP; EGF but not LPA or S1P stimulates further phosphorylation. FAK is phosphorylated in response to both LPA and S1P in PC-3 and Du145, but not in LNCaP. LPA and S1P stimulate phospholipase D (PLD) activity to varying extents in the different cell lines. Notably, both lipid mediators activate PLD in LNCaP. In Du145, LPA, but not S1P, activates PLD and enhances cellular production of LPA.
    Conclusions: Although both LPA and S1P induce signal transduction in all prostate cancer cell lines studied, a proliferation response is observed only when the Erk, Akt, and FAK pathways are activated. Other responses to the lipid mediators, such as PLD activation, likely contribute to other cellular outcomes.
    MeSH term(s) Cell Division/drug effects ; Cell Division/physiology ; Cell Line, Tumor ; Culture Media, Serum-Free/pharmacology ; Enzyme Activation/drug effects ; Gene Expression Regulation, Neoplastic ; Humans ; Isomerism ; Lysophospholipids/metabolism ; Lysophospholipids/pharmacology ; Male ; Phosphorylation/drug effects ; Phosphorylation/physiology ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; RNA, Messenger/metabolism ; Receptors, Lysophosphatidic Acid/chemistry ; Receptors, Lysophosphatidic Acid/genetics ; Receptors, Lysophosphatidic Acid/metabolism ; Receptors, Lysosphingolipid/genetics ; Receptors, Lysosphingolipid/metabolism ; Signal Transduction/drug effects ; Signal Transduction/physiology ; Sphingosine/analogs & derivatives ; Sphingosine/metabolism ; Sphingosine/pharmacology ; Tyrosine/metabolism
    Chemical Substances Culture Media, Serum-Free ; Lysophospholipids ; RNA, Messenger ; Receptors, Lysophosphatidic Acid ; Receptors, Lysosphingolipid ; S1PR1 protein, human ; sphingosine 1-phosphate (26993-30-6) ; Tyrosine (42HK56048U) ; Sphingosine (NGZ37HRE42) ; lysophosphatidic acid (PG6M3969SG)
    Language English
    Publishing date 2009-10-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 604707-5
    ISSN 1097-0045 ; 0270-4137
    ISSN (online) 1097-0045
    ISSN 0270-4137
    DOI 10.1002/pros.20994
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top